What are the scoring tools used for deep vein thrombosis (DVT) prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Scoring Tools for DVT Prophylaxis

The two primary validated scoring tools for DVT prophylaxis risk stratification are the Padua Prediction Score and the IMPROVE VTE Risk Assessment Model, both of which should be used to assess thromboembolism risk prior to initiating prophylaxis in hospitalized medical patients. 1

Primary Risk Assessment Tools

Padua Prediction Score

The Padua score is a validated tool that stratifies VTE risk in hospitalized medical patients using the following criteria 1:

  • Active cancer (metastatic or receiving chemotherapy): 3 points
  • Previous VTE (excluding superficial thrombophlebitis): 3 points
  • Reduced mobility (bed rest with bathroom privileges ≥3 days): 3 points
  • Known thrombophilic condition: 3 points
  • Recent trauma and/or surgery (<1 month): 2 points
  • Elderly age (>70 years): 1 point
  • Heart and/or respiratory failure: 1 point
  • Acute myocardial infarction or ischemic stroke: 1 point
  • Ongoing hormonal treatment: 1 point
  • Obesity (BMI >30): 1 point
  • Acute infection and/or rheumatologic disorder: 1 point

Risk stratification interpretation: A Padua score of 0-3 indicates low risk (VTE incidence 0.3%), while a score ≥4 indicates high risk (VTE incidence 11% without prophylaxis, reduced to 2.2% with prophylaxis, HR 0.13). 1

IMPROVE VTE Risk Assessment Model

The IMPROVE VTE score provides an alternative validated approach 1:

  • Previous VTE: 3 points
  • Known thrombophilia (congenital or acquired): 2 points
  • Lower limb paralysis (leg falls to bed by 5 seconds but has some effort against gravity): 2 points
  • Active cancer: 2 points
  • Immobilization >7 days: 1 point
  • ICU/CCU stay: 1 point
  • Age >60 years: 1 point

Risk stratification interpretation: Score 0-1 = low risk (0.5% VTE rate), score 2-3 = moderate risk (1.5% VTE rate), score ≥4 = high risk (5.7% VTE rate). A score ≥2 indicates need for VTE prophylaxis. 1

Bleeding Risk Assessment Tool

IMPROVE Bleeding Risk Assessment Model

This complementary tool assesses bleeding risk to balance prophylaxis decisions 1:

  • Platelet count <50 × 10⁹/L: 4 points
  • Bleeding in 3 months before admission: 4 points
  • Active gastroduodenal ulcer: 4.5 points
  • Age >85 years: 3.5 points
  • Hepatic failure (INR >1.5): 2.5 points
  • Renal failure (GFR <30 mL/min per m²): 2.5 points
  • ICU/Critical Care Unit stay: 2.5 points
  • Central venous catheter: 2 points
  • Rheumatic disease: 2 points
  • Current cancer: 2 points
  • Age 40-80 years: 1.5 points
  • Renal failure (GFR 30-59 mL/min per m²): 1 point
  • Male sex: 1 point

Bleeding risk interpretation: Score <7 indicates low bleeding risk (0.4% major bleeding/1.5% any bleeding), while score ≥7 indicates high bleeding risk (4.1% major bleeding/7.9% any bleeding). 1

Clinical Application Algorithm

Step 1: Calculate Padua score or IMPROVE VTE score for all hospitalized medical patients 1

Step 2: If Padua score ≥4 or IMPROVE VTE score ≥2, calculate IMPROVE bleeding score 1

Step 3: Make prophylaxis decision based on combined assessment 1:

  • High VTE risk + low bleeding risk (IMPROVE bleeding <7): Initiate pharmacologic prophylaxis with LMWH or UFH
  • High VTE risk + high bleeding risk (IMPROVE bleeding ≥7): Use mechanical prophylaxis (IPC devices) instead of pharmacologic methods 2
  • Low VTE risk: Early ambulation alone is sufficient 2

Common Pitfalls to Avoid

Do not apply universal VTE prophylaxis without risk assessment, as the American College of Physicians explicitly does not support performance measures promoting universal prophylaxis regardless of risk. 1

Do not use graduated compression stockings as primary prophylaxis, as the American College of Physicians strongly recommends against their use for VTE prevention in medical patients. 1

Do not overlook bleeding risk assessment, as pharmacologic prophylaxis increases bleeding events (RR 1.34, absolute increase 9 events per 1000 persons) despite reducing PE (RR 0.69, absolute reduction 4 events per 1000 persons). 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Deep Vein Thrombosis Prophylaxis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended prophylaxis for patients at risk of developing Deep Vein Thrombosis (DVT)?
What types of prophylaxis are recommended for patients at risk of Deep Vein Thrombosis (DVT)?
Do patients on Dapt (Dabigatran) require Deep Vein Thrombosis (DVT) prophylaxis (PPX) as inpatients?
Is epistaxis (nosebleed) a contraindication for Deep Vein Thrombosis (DVT) prophylaxis postoperatively?
Does a 75-year-old man with type 2 diabetes, BMI 31, and recent open laparotomy (surgical incision in the abdominal cavity) for perforated appendix require prophylaxis for Deep Vein Thrombosis (DVT)?
What is the recommended treatment for a patient with a history of lymphoma and malignant pleural effusion who develops chylothorax, specifically using octreotide (somatostatin analogue)?
Can a patient on Cymbalta (duloxetine) 20mg and Vyvanse (lisdexamfetamine) 20mg experience withdrawal symptoms, including rebound anxiety, after missing one day of medication due to a colonoscopy, or could the symptoms be related to medications administered during the procedure?
What is the step-by-step procedure for cannulated screw (CC) fixation in a patient with an intracapsular neck of femur fracture?
What is the recommended prefilter fluid administration strategy to decrease clotting in the Continuous Renal Replacement Therapy (CRRT) circuit for a critically ill patient with acute kidney injury?
What is the diagnosis and management for a patient with hypokalemia, hypomagnesemia, and hypochloremia, with a complex acid-base disorder, in the context of underlying liver disease and bile duct issues, and total parenteral nutrition (TPN) therapy?
What is the recommended dose of octreotide (somatostatin analogue) for a patient with a history of lymphoma and malignant pleural effusion who has developed chylothorax and persistent pleural effusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.